Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.
Press releases published on May 12, 2025
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
GlobeNewswire
·
May 12, 2025
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 …
Collegium Announces $25 Million Accelerated Share Repurchase Program
GlobeNewswire
·
May 12, 2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it …
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
GlobeNewswire
·
May 12, 2025
DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “ …
ASML reports transactions under its current share buyback program
GlobeNewswire
·
May 12, 2025
ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average …
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
GlobeNewswire
·
May 12, 2025
LEIDEN, Netherlands …
STMicroelectronics Announces Status of Common Share Repurchase Program
GlobeNewswire
·
May 12, 2025
STMicroelectronics Announces Status of Common Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 5, 2025 to May 9, 2025 AMSTERDAM – May 12, 2025 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global …
CPS Technologies to Participate in Sidoti Microcap Virtual Conference
GlobeNewswire
·
May 12, 2025
NORTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that, as it did last year, the Company will participate in the Sidoti Microcap Virtual Conference on May 21 and 22, 2025. A …
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference …
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire
·
May 12, 2025
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer …
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire
·
May 12, 2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In- …
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
GlobeNewswire
·
May 12, 2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder …
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
GlobeNewswire
·
May 12, 2025
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell …
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 12, 2025
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities …
nuVizz and Ford Motor Company to Share Keys to 96% Parts Delivery Success at Home Delivery World
GlobeNewswire
·
May 12, 2025
ATLANTA, May 12, 2025 (GLOBE NEWSWIRE) -- nuVizz, a leading innovator in last-mile transportation management solutions (TMS), will present alongside Ford Motor Company at Home Delivery World 2025, one of North America’s premier logistics and supply chain …
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire
·
May 12, 2025
WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Longevity Health Holdings, Inc. Announces Reverse Stock Split
GlobeNewswire
·
May 12, 2025
PITTSBURGH, May 12, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (NASDAQ: XAGE) (“Longevity” or the “Company”), a bio-aesthetics company focused on longevity and healthy aging, today announced that it has resolved to effect a reverse stock …
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
GlobeNewswire
·
May 12, 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community …
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 12, 2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB …
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …